CBMG - Cellular Biomedicine Inc News Story
$18.24 0.2 1.3%
Last Trade - 22/01/21
| Market Cap | £259.6m |
| Enterprise Value | £275.6m |
| Revenue | £236k |
| Position in Universe | 3725th / 6630 |
BRIEF-Cellular Biomedicine Says Application Accepted By NMPA For Clinical Trial In China For ANTI-BCMA CAR-T
Fri 3rd April, 2020 10:43pm
April 3 (Reuters) - Cellular Biomedicine Group Inc CBMG.O :
* CELLULAR BIOMEDICINE - ON MARCH 31, CO'S APPLICATION
ACCEPTED BY
NMPA FOR CLINICAL TRIAL IN CHINA FOR ANTI-BCMA CAR-T FOR
RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Source text: https://bit.ly/2UVysOO
Further company coverage: CBMG.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cellular Biomedicine Inc
See all news
